$heff's $tation of $tocks & $olid DD

[buckiii2]

Athersys Announces Results From Phase 2 Study of MultiStem(R) Cell Therapy for Treatment of Ischemic Stroke
Athersys, Inc.
15 minutes ago
GlobeNewswire
????
CLEVELAND, April 17, 2015 (GLOBE NEWSWIRE) -- Athersys, Inc. (ATHX) today announced interim results from its exploratory Phase 2 clinical study of the intravenous administration of MultiStem(R) cell therapy to treat patients who have suffered an ischemic stroke. The study results demonstrate favorable safety and tolerability for MultiStem, consistent with prior studies. With respect to the primary and secondary endpoints, the cell therapy did not show a difference at 90 days compared to placebo. However, MultiStem treatment was associated with lower rates of mortality and life threatening adverse events (AEs), infections and pulmonary events. Furthermore, post-hoc analysis shows that patients who received MultiStem treatment earlier in the treatment window had more robust recovery rates in comparison to placebo and relative to patients who received later MultiStem treatment.

Dr. David Hess, lead clinical investigator in the study, stroke specialist and Chairman of the Department of Neurology at the Medical College of Georgia at Georgia Regents University, will present the summary results at the European Stroke Organization conference on Sunday, April 19th at 8:50 AM in Glasgow, Scotland, United Kingdom.

Data highlights from the 90-day interim analysis include:
http://finance.yahoo.com/news/athersys-announces-results-phase-2-100000147.html